Rambachan Aksharananda, Fang Margaret C
Division of Hospital Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
J Gen Intern Med. 2025 Apr 25. doi: 10.1007/s11606-025-09514-6.
Adequate pain management is challenging in patients with substance use disorders, particularly those from racial/ethnic minority groups who face intersecting biases.
To investigate inequities in pain management for racial/ethnic minority groups with and without concurrent substance use disorders.
Retrospective cohort study from 2021 to 2022 on an acute care general medicine service at UCSF Medical Center.
All adults ≥ 18 years old.
Primary exposure was the patient's self-identified race/ethnicity (Asian, Black or African American, Latino, Multi-Race/Ethnicity, Native American or Alaska Native, Native Hawaiian or Pacific Islander, Southwest Asian or North African, White, Other, and Unknown/Declined).
The primary outcome was average daily inpatient opioids received (morphine milligram equivalents, MME). Multivariable negative binomial regression assessed the relationship between self-reported race/ethnicity and opioid administration, adjusting for demographics, clinical factors, substance use disorders, and pain characteristics. The subgroup analyses focused on patients with substance use disorders and on patients without any buprenorphine or methadone prescriptions.
In the overall cohort of 13,058 hospitalizations (mean age 62.7 years, 51.2% male, 31.3% with substance use disorder), patients from racial/ethnic minority groups received significantly fewer opioids than White patients in adjusted analyses: Asian (- 61.3 MME/day), Black (- 44.9 MME/day), Latino (- 48.8 MME/day), Native American/Alaska Native (- 80.4 MME/day), and Native Hawaiian/Pacific Islander (- 72.9 MME/day). Similar, significant disparities were present in both subgroups. Notably, in the substance use disorder-only subgroup (n = 4446), larger disparities persisted for Asian (- 124.4 MME/day), Black (- 68.7 MME/day), and Latino (- 110.8 MME/day) patients compared to White patients.
Substantial racial/ethnic inequities in inpatient opioid prescribing for pain control were observed, particularly among patients with concurrent substance use disorders. These findings highlight the need for interventions promoting equitable, culturally competent pain management for marginalized populations facing intersecting biases and stigma.
对患有物质使用障碍的患者进行充分的疼痛管理具有挑战性,尤其是那些来自面临多重偏见的种族/族裔少数群体的患者。
调查患有和未患有并发物质使用障碍的种族/族裔少数群体在疼痛管理方面的不平等情况。
2021年至2022年在加州大学旧金山分校医学中心的急性护理普通内科服务部门进行的回顾性队列研究。
所有年龄≥18岁的成年人。
主要暴露因素是患者自我认定的种族/族裔(亚洲人、黑人或非裔美国人、拉丁裔、多种族/族裔、美洲原住民或阿拉斯加原住民、夏威夷原住民或太平洋岛民、西南亚或北非、白人、其他以及未知/拒绝回答)。
主要结局是住院期间每日平均接受的阿片类药物量(吗啡毫克当量,MME)。多变量负二项回归分析评估了自我报告的种族/族裔与阿片类药物使用之间的关系,并对人口统计学、临床因素、物质使用障碍和疼痛特征进行了调整。亚组分析重点关注患有物质使用障碍的患者以及没有任何丁丙诺啡或美沙酮处方的患者。
在总共13058例住院病例(平均年龄62.7岁,51.2%为男性,31.3%患有物质使用障碍)的总体队列中,在调整分析中,种族/族裔少数群体患者接受的阿片类药物明显少于白人患者:亚洲人(-61.3 MME/天)、黑人(-44.9 MME/天)、拉丁裔(-48.8 MME/天)、美洲原住民/阿拉斯加原住民(-80.4 MME/天)以及夏威夷原住民/太平洋岛民(-72.9 MME/天)。两个亚组中均存在类似的显著差异。值得注意的是,在仅患有物质使用障碍的亚组(n = 4446)中,与白人患者相比,亚洲人(-124.4 MME/天)、黑人(-68.7 MME/天)和拉丁裔(-110.8 MME/天)患者的差异更大。
观察到在住院患者阿片类药物处方用于疼痛控制方面存在严重的种族/族裔不平等,尤其是在患有并发物质使用障碍的患者中。这些发现凸显了需要采取干预措施,为面临多重偏见和污名的边缘化人群促进公平、具有文化胜任力的疼痛管理。